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Li Xing1,2*, Xia Zhao1,2, Fei Guo3 and Lawrence Kleiman1,2*Abstract
Background: RNA helicase A (RHA), a DExH box protein, promotes annealing of tRNALys3, a primer for reverse
transcription, to HIV-1 RNA and assembles into virus particles. A-kinase anchoring protein 95-like protein (HAP95) is
a binding partner of RHA. The role of HAP95 in the annealing of tRNALys3 was examined in this study.
Results: HAP95 associates with the reverse transcriptase region of Pol protein of HIV-1. Decreasing endogenous
HAP95 in HIV-1-producing 293T cells by siRNA reduces the amount of tRNALys3 annealed on viral RNA. This defect
was further deteriorated by knockdown of RHA in the same cells, suggesting a cooperative effect between these
two proteins. Biochemical assay in vitro using purified GST-tagged HAP95 shows that HAP95 may inhibit the activity
of RHA.
Conclusion: The results support a hypothesis that HAP95 may transiently block RHA’s activity to protect the
annealed tRNALys3 on viral RNA in the cells from removing by RHA during the packaging of RHA into virus particles,
thus facilitating the annealing of tRNALys3 to HIV-1 RNA.
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Reverse transcription is a signature step of retrovirus repli-
cation that produces minus strand strong stop cDNA
(ssscDNA) upon infection of the new cells. Reverse tran-
scriptase (RT) is the major enzyme responsible for reverse
transcription and was released from Pol by proteolytic
cleavage of a polyprotein precursor Gag-Pol during the
budding of virus particles [1]. HIV-1, a member of lenti-
virus family of retroviridae, selectively packages tRNALys3
into virus particle and anneals tRNALys3 to viral genomic
RNA as a primer in reverse transcription [2]. The annealing
of tRNALys3 consists of the hybridization of the 3’ terminal
18 nucleotides (nts) of tRNALys3 to a complementary se-
quence of 18 nts termed the primer binding site (PBS) of
HIV-1 genomic RNA and several other distinct base-paring
interactions between tRNALys3 and viral RNA sequences
upstream of PBS including the tRNALys3 anticodon
complimentary to a small single-stranded A-rich loop [3],
the 5’ part of the TYC arm complementary to 8 nts primer* Correspondence: xingli107@gmail.com; Lawrence.kleiman@mcgill.ca
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unless otherwise stated.activation site (PAS) [4], and 6 nts sequence containing
part of variable loop complementary to a cytidine-rich re-
gion upstream of viral A-rich loop [5].
A number of viral and cellular protein factors partici-
pate in reverse transcription-associated activities of HIV-1
[6]. For instance, Gag plays crucial roles in a variety of re-
verse transcription-related activities including the incorpor-
ation of viral genomic RNA into virions [7], the dimerization
of viral genomic RNA [8], and the tRNALys3 annealing to
viral genomic RNA [9]. The annealing of tRNALys3 to viral
genomic RNA was initially mediated by Gag [10,11] and
then fine-tuned by nucleocapsid (NC) protein, a proteo-
lytic derivative of Gag during budding of virus particles, to
render the annealed tRNALys3 an increased capability as a
reverse transcription primer [12,13].
Human RNA helicase A (RHA), also known as DHX9, is
a member of DExD/H box protein family and has also been
shown involved in reverse transcription-related activity of
HIV-1. For example, RHA has been shown to promote the
annealing of tRNALys3 to viral RNA [14] and is packaged
into HIV-1 particles [15]. Knockdown of endogenous
RHA by RNAi technique in virus-producing cells results
in reduced annealing of tRNALys3 to viral RNA in progeny
virions.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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HAP95, HA95, or NAKAP95, is a product of gene dupli-
cation of A-kinase anchoring protein 95 (AKAP95) [16,17]
and regulates a variety of physical or pathological pro-
cesses including chromatin condensation, and initiation of
DNA replication [16,18], pre-mRNA splicing [19], patho-
genesis of Huntington’s disease (HD) [20], and oncogen-
esis [21]. HAP95 was identified as a cellular binding
partner of RHA [22] and can synergize with RHA to acti-
vate the cis-acting constitutive transport element (CTE)-
mediated gene expression of type D retroviruses [23]. In
analysis of HIV-1 Pol protein complex, we found that
HAP95 associates with RT part of Pol. Thus, we wonder
whether HAP95 executes a role in reverse transcription-
related activities of HIV-1. We found that knockdown of
HAP95 in virus-producing 293T cells does not affect
the production of HIV-1 particle nor does the viral RNA
packaging, but reduces the annealing of tRNALys3 to viral
RNA. This defect in tRNALys3 annealing was deteriorated
by knockdown of RHA in the same cells. However,
in vitro tRNALys3 annealing assay using purified GST-
tagged HAP95 revealed that HAP95 inhibits the activity of
RHA. These seemingly contradictory observations suggest
that HAP95 may work as a negative regulator for the ac-
tivity of RHA in promotion of tRNALys3 annealing.
Results
HAP95, an RHA binding protein, associates with reverse
transcriptase region of HIV-1 Pol protein and is incorporated
into HIV-1 particles upon overexpression
The TAP (tandem affinity protein purification system)
method has been widely used to study the protein com-
plex in the cell. Roy et al. used this method to study the
cellular proteins that associate with HIV-1 Gag [15] and
identified RHA that is incorporated into HIV-1 particles
and promotes the synthesis of viral cDNA upon viral in-
fection of the new cells. Pol consists of protease, RT and
integrase (INp32). Both Pol and its processed product
RT play important roles in the selection of tRNALys3 as a
primer for HIV-1 reverse transcription [24,25]. In this
report, we used TAP to identify cellular proteins binding
to the Pol part of HIV-1 Gag-Pol polyprotein. A plasmid
pcDNA3-N-TAP-hPol was constructed and the Pol pro-
tein encoded by this plasmid has amino acid sequence
identical to that of HIV-1 NL4-3 Pol, but the mRNA se-
quence has their codons optimized for mammalian cell
codon usage. 293T cells were stably transfected with
pcDNA3-N-TAP-hPol. TAP-Pol associated proteins were
isolated by two-step affinity chromatography, resolved
in 1D sodium dodecyl sulfate (SDS)-polyacrylamide gels
(PAGE). The proteins in different bands were identified by
mass spectrometry analysis. One of the proteins associated
with Pol was found to be HAP95, an RHA binding
protein [22,23]. We then determined whether HAP95coprecipitates with RTp66 or INp32 by cotransfecting
293 T cells with DNAs expressing Flag-HAP95 and either
His-RTp66 or His-INp32. Figure 1A show the ability of
Flag-HAP95 to be coprecipitated with RTp66 from cellu-
lar lysates. Western blots of cellular lysates probed with
anti-Flag or anti-His (upper panel) show the expression of
Flag-HAP95 or His-RTp66 and His-INp32 in the cells.
Western blots of the precipitates probed with either anti-
His or anti-Flag (lower panel) show that Flag-HAP95
coprecipitates with RTp66, but not with INp32.
One implication of Pol-HAP95 association is the in-
corporation of HAP95 into virus particles. To test this
hypothesis, 293 T cells were cotransfected with SVC21.
BH10 containing full-length HIV-1 BH10 proviral DNA
and a plasmid expressing Flag-HAP95 or only Flag tag.
The virus particles thus produced were purified through
step sucrose centrifugation and analyzed by Western
blotting using anti-Flag or anti-HAP95. HAP95 was not
detected in the virus particles until it was over-expressed
(Figure 1B). This observation was further confirmed by
the analysis of core of HIV-1 particles (Figure 1C). The
purified virus particles containing Flag-HAP95 were first
treated with Triton X-100 to deplete the virus envelope.
After extensive washing, the viral core pellet was assessed
for the presence of viral envelope protein (gp120) and re-
tention of HAP95. The results of Western blotting show
that the envelope protein was removed by treatment with
Triton X-100, and that the RT, CAp24, and HAP95 were
recovered with the viral core pellets, indicating that
HAP95 was packaged in the virus particles. As expected,
RHA was readily detected in the cells and in the HIV-1
particles (Figure 1B and C). Moreover, the level of RHA in
virus particles was not changed obviously by the incorpor-
ation of HAP95 into virus particles.
In order to test the role of Pol in the incorporation of ex-
ogenous HAP95 into HIV-1 particles, we analyzed virus-
like particles (VLPs) of Gag or of Gag/Gag-Pol. These two
kinds of VLPs were produced in 293T cells expressing
Flag-tagged HAP95 (Figure 1D). Gag VLP contains
unprocessed Gag-pr55. Gag/Gag-Pol VLP mainly contains
the processed Gag and Pol. The expression of functional
Pol was demonstrated by the detection of unprocessed
Gag-Pol in Gag/Gag-Pol VLP-producing 293T cells (left
panel) and processed products of Pol, RTp66/51 in puri-
fied Gag/Gag-Pol VLP (right panel) using anti-p24 and
anti-RT respectively. Flag-tagged HAP95 was detected in
Gag/Gag-Pol VLP instead of Gag VLP, suggesting a role of
Pol in the incorporation of overexpressed HAP95 into
virus particles.
HAP95 is not required for production of HIV-1 particle,
but is important for infectivity of progeny virion
To study the role of HAP95, we analyzed the production















































































Figure 1 Incorporation of HAP95 into HIV-1 particles upon overexpression. (A) Co-precipitation of HAP95 with His-tagged RTp66. 293 T cells
were cotransfected with DNAs encoding for Flag-HAP95 and either His-tagged RTp66 or His-tagged INp32, or His tag. Upper panels show Western
blots of cell lysates probed with either anti-Flag or anti-His. The cell lysates were then incubated and precipitated with Ni-NTA agarose. The lower
panels show the Western blots of the precipitates probed with either anti-His or anti-Flag. •, non-specific protein bands. The His-tag peptide alone
was not detected in these Western blots. (B) Association of HAP95 with purified HIV-1 particles. 293 T cells were cotransfected with DNAs encoding
for HIV-1 BH10 and either Flag-HAP95 or Flag tag. Upper panels show the Western blots of cell lysates probed with anti-HAP95, anti-Flag, anti-RHA,
and anti-β-actin. Lower panels show the Western blots of purified HIV-1 particles probed with anti-HAP95, anti-Flag, anti-RHA, anti-p24, and anti-RT.
(C) HIV-1 particles containing Flag-HAP95 were treated with Triton X-100. The viral cores were isolated and analyzed by Western blotting using
anti-gp120, anti-p24, anti-RT, anti-HAP95, anti-Flag, and anti-RHA. (D) Incorporation of HAP95 into VLP. 293T cells were cotransfected with
DNAs encoding for Flag-HAP95 and either BH10 Gag or BH10 Gag/Gag-Pol. VLPs were purified by step sucrose centrifugation at 48 hours
posttransfection. Cell lysates and VLPs were analyzed by Western blotting using anti-p24, anti-Flag, anti-HAP95, anti-β-actin, or anti-RT. M, protein
size marker shown in kDa.
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or siRNAHAP, and 16 hours later, were transfected with
SVC21.BH10 DNA coding for HIV-1 BH10. Western blots
of cell lysates probed with anti-HAP95 or anti-RHA
shows that HAP95 was effectively reduced by siRNAHAP,
but the level of RHA was not changed (Figure 2A). The
production of extracellular HIV-1 particles was deter-
mined by measuring the amount of CAp24 at the indi-
cated time points posttransfection. The results show that
knockdown of HAP95 did not affect the yields of virus
particles over the time course (Figure 2B). However, in
single-cycle infectivity assay, we found that the reduced
HAP95 affected the infectivity of produced virus particles.Thus, challenging TZM-bl indicator cells with viruses
produced in the cells treated with siRNAHAP resulted
in reduction in the induced luciferase activity in the
cell lysates (Figure 2C).
HAP95 is not required for viral RNA packaging, but is
important for the annealing of tRNALys3 to HIV-1 RNA
We then analyzed the incorporation of viral RNA and
tRNALys3 in the virus particles by performing dot blot
hybridization and real-time RT-PCR. The total viral
RNA was isolated from equal amounts (about 500 ng of
CAp24) of each virus preparation. In dot blot hybridization,
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Figure 2 Decreased cellular HAP95 does not affect the production of HIV-1 particles, but reduces the infectivity of virus particles.
293 T cells were treated with siRNACon or siRNAHAP, and 16 hours later, were transfected with DNA encoding for HIV-1 BH10. (A) Cell lysates were
prepared at 24 hours posttransfection of DNA and analyzed by Western blotting using anti-HAP95, anti-RHA, or anti-β-actin. (B) The extracellular
culture medium was analyzed by CAp24 ELISA assay at the indicated time points posttransfection of DNA to determine the amount of virus particles.
(C) Viral infectivity assay. HIV-1 particles were purified at 48 hours posttransfection of DNA and the single-round viral infectivity was measured by
challenging TMZ-b1 cell with purified viruses corresponding to 5 ng of CAp24. The induced luciferase activity was determined at 24 hours later and
the results were normalized to that of virions produced from siRNACon-treated cells. Shown are the mean values ± standard deviation (SD) of results of
3 experiments. *, P <0.05.
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gions of HIV-1 RNA genome or with 32P-labeled DNA
probe specific to tRNALys3. The samples obtained from
mock- transfected cells were used as a negative control.
The results were analyzed using a PhosphorImager instru-
ment. Neither dot blot hybridization nor real-time RT-PCR
detected the obvious change in viral RNA incorporation as
a result of reduction in HAP95 content in virus-producing
cells (Figure 3A and C). The packaging of tRNALys3
remains unchanged as well (Figure 3B and D).
To determine whether the reduced viral infectivity re-
flects an alteration in the annealing of tRNALys3 to viral
RNA, we examined the ability of tRNALys3 to be extended
in an in vitro reverse transcription system, using deprotei-
nized total viral RNA as the source of primer tRNALys3
annealed in vivo to viral genomic RNA. The relative
amount of tRNALys3 annealed to viral RNA is determined
by +6 nt extension under conditions in which all other re-
agents in the reaction are in excess, so that the amount of
tRNALys3 extended is proportional to the amount of total
viral RNA in the reaction mixture [10]. We have also ex-
amined incorporation of the first dNTP, dCTP, into
tRNALys3 annealed to viral RNA (+1 nt extension).
Figure 4A (upper panel) shows the 1D PAGE patterns of
both +6 and +1 nt extension products using viral RNA.
Equal amounts of viral genomic RNA, determined by dot
blot hybridization, were used in these reactions, and this
was further tested for with a control (control panel) that
involves annealing a DNA primer complementary to viral
RNA sequences downstream of the PBS and extending
it by +6 nt. The results were quantitated, normalized
to results obtained with siRNACon, and shown graph-
ically in lower panel. Knockdown of endogenous HAP95
results in reductions in both +6 nt and +1 nt extension of
tRNALys3. The ability of exogenous HAP95 to rescue thereduced annealing of tRNALys3 due to reduced endogen-
ous HAP95 was examined next. 293T cells were first
treated with siRNACon or siRNAHAP, and 16 hours later,
were cotransfected with SVC21.BH10 and a vector coding
either Flag tag only or Flag-HAP95-r. Flag-HAP95-r has
the amino acid sequence identical to that of Flag-HAP95,
but the encoding mRNA lacks the siRNAHAP target
sequence. The Western blots of cell and viral lysates
(Figure 4B) show that the reduction in endogenous
HAP95 by siRNAHAP is rescued by Flag-HAP95-r. This
exogenous HAP95 results in a detectable presence of this
molecule in the virion. The viral content of RTp66/51,
relative to CAp24, remains unaffected. As a result of the
expression of exogenous HAP95, the tRNALys3 annealing
(Figure 4C) and the viral infectivity (Figure 4E) that were
reduced by siRNAHAP are now increased over that ob-
tained in the presence of siRNACon although the pack-
aging of tRNALys3 into virus particles remains unchanged
(Figure 4D). We further examined the in vivo reverse
transcription activity of tRNALys3-viral RNA complex by
measuring the level of newly synthesized ssscDNA using
real-time PCR after the virus infection of SupT1 cells
(Figure 4F). The amounts of viral RNA were determined
by real-time RT-PCR as a control. The results show that
the virus particles produced from cells containing de-
creased HAP95 generated significantly less ssscDNAs com-
pared with that of viruses produced from siRNACon-treated
cells or Flag-HAP95-r-expressing cells. These results im-
plicate an important role of HAP95 in the annealing of
tRNALys3.
Effect of knockdown of both RHA and HAP95 upon
annealing of tRNALys3 to HIV-1 RNA
Since HAP95 is an RHA binding protein [22,23] and
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Figure 3 Decreased cellular HAP95 does not affect the incorporation of viral RNA and tRNALys3 into HIV-1 particles. Total viral RNA was
isolated from equal amounts of purified HIV-1 particles. The abundance of viral RNA or tRNALys3 was determined by hybridizing dot blots of total
viral RNA with 32P-labeled DNA probes specific for HIV-1 RNA or tRNALys3 and quantitating radioactive signals using a PhosphorImager instrument.
The results were normalized to that of virions produced from siRNACon-treated cells and presented in percentage. (A) Upper panel: Diagram of
HIV-1 genomic organization and the positions of 3 DNA probes used in dot blot hybridization. Numbers indicate the nucleotide positions relative
to the start site (+1) of transcription of HIV-1 genomic RNA. Lower panel: A representative of dot blots probed with 3 DNA probes in triplicate
(left part, 1, 2, and 3) and a graph showing the relative abundance of viral genomic RNA in HIV-1 virions (right part). m, samples obtained from
mock-transfected cells. (B) A representative of dot blots probed with tRNALys3 probe in triplicate (upper panel, 1, 2, and 3) and a graph showing
the relative abundance of tRNALys3 in HIV-1 virions (lower panel). (C, D) Quantitation of viral RNA and tRNALys3 in HIV-1 particles by real-time
RT-PCR. Shown are the averages of fold change ± SD of 3 experiments.
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ied the effects of reducing both RHA and HAP95 upon
the annealing of tRNALys3 to viral RNA. 293T cells were
treated with different siRNAs, and 16 hours later, were
transfected with SVC21. BH10. Figure 5 shows the ef-
fects of siRNAs to RHA or HAP95, separately or to-
gether, upon +6 nt extension of tRNALys3 by reverse
transcription. Figure 5A shows the levels of proteins in
the cell or in the virion. The blots of cellular lysate indi-
cate the expected decrease in expression of either RHA or
HAP95 in the presence of either siRNARHA or siRNAHAP
respectively. Similarly, in the viral lysate, RHA was re-
duced in the presence of siRNARHA alone or together with
siRNAHAP.
The effects of decreasing endogenous RHA or HAP95,
or RHA and HAP95 together, upon +6 nt extension of
tRNALys3 (Figure 5B) and viral infectivity (Figure 5C)
were measured. Quantitative values are presented graph-
ically. These results show that reducing both HAP95and RHA has a greater inhibitory effect on either the an-
nealing of tRNALys3 or viral infectivity than reducing ei-
ther one.
HAP95 inhibits activity of RHA in vitro
RHA promotes the Gag-mediated annealing of tRNALys3
to viral RNA both in vivo and in vitro [14]. To study the
effect of HAP95 upon the RHA-induced promotion of
tRNALys3 annealing in vitro, a 386 nts synthetic HIV-1
RNA was 3’-end labeled with 32pCp. GST-tagged HAP95
was purified from 293E cells, as shown by Western blot
analysis (Figure 6A). The in vitro tRNALys3 annealing assay
was performed using the purified proteins and the reac-
tion mixture was resolved in native 1D PAGE (Figure 6B).
When annealing is facilitated with Gag in vitro, three
tRNALys3-viral RNA complex bands of different electro-
phoretic mobility (slow, middle, and fast) were detected,
with the middle band being the dominant species [14]









































































































































































































Figure 4 Decreased cellular HAP95 results in reduced annealing of tRNALys3 to viral RNA. (A) Total viral RNA was isolated from purified
HIV-1 particles, and tRNALys3 annealed to viral RNA in the cell was extended using reverse transcriptase by either 6 nucleotides (+6 nt) or 1 nt
(+1 nt). Upper panel: The extended tRNALys3 products are resolved by 1D PAGE. The control gel shows that equal amounts of viral RNA were used
in each extension reaction. Lower panel: The relative amounts of +6 or +1 nt extended tRNALys3 products are represented graphically. Shown are
the mean values ± SD of 3 experiments. *, P < 0.05. (B) Rescue of the annealing of tRNALys3 inhibited by siRNAHAP by expression of HAP95 mRNA
resistant to siRNAHAP. Upper panel: Western blots of cellular lysates probed with anti-HAP95, anti-Flag, or anti-β-actin. Lower panel: Western blots
of viral lysates containing equal amounts of CAp24. (C) +6 nt extension assay. Upper panel: +6 nt-extended tRNALys3 detected in 1D PAGE. Lower
panel: The relative amounts of +6 nt extended tRNALys3 products are represented graphically. *, P < 0.05 compared to the results obtained with
virions produced from the cells expressing Flag tag only. (D) Quantitation of tRNALys3 in HIV-1 particles by real-time RT-PCR. Shown are the
averages of fold change ± SD of 3 experiments. (E) Viral infectivity assay was performed as described in Figure 2 legend. *, P < 0.05 compared to
the results obtained with virions produced from the cells expressing Flag tag only. (F) HIV-1 cDNA synthesis in the newly BH10-infected SupT1
cells. The amounts of viral RNA or newly synthesized cDNA in the cells were quantitated by real-time RT-PCR or real-time PCR. *, P < 0.05
compared to the results obtained with virions produced from the cells expressing Flag tag only.
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amined the effect of adding RHA to the annealing reaction
in the presence of GST or GST-HAP95. All reactions con-
tain the ATP required for RHA activity. RHA facilitates
the annealing of tRNALys3 to viral RNA by increasing the
amount of the slow migrating tRNALys3-viral RNA com-
plex [14] (Figure 6B, lane 5). This increase was compro-
mised by the presence of GST-HAP95 (Figure 6B, lanes 8
and 9), but not GST tag alone (Figure 6B, lanes 6 and 7).
However, GST-HAP95 did not affect the formation of
middle migrating bands (Figure 6B, lane 4), indicating that
HAP95 may inhibit the activity of RHA, but not Gag.Additionally, a recent report shows that the annealing of
tRNALys3 to the sequence within the primer binding site
of HIV-1 facilitates the dimerization of viral RNA [26].
This observation increases the possibility that the slow mi-
grating bands shown in Figure 6B would be a dimerized
tRNALys3-annealed viral RNA. Thus, the identities of the
tRNALys3-viral RNA complexes formed in in vitro assay
has yet to be further determined.
Discussion
In this work, we studied the role of HAP95, a binding
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Figure 5 Effect of knockdown of RHA and HAP95 together
upon the annealing of tRNALys3 to viral RNA. 293 T cells were
first treated with siRNACon, siRNARHA, or siRNAHAP, or with both
siRNARHA and siRNAHAP, and 16 hours later, were transfected with
DNA coding for HIV-1 BH10. (A) Western blots of cell or viral lysates
were probed with antibodies against RHA, HAP95, β-actin, CAp24, or
RTp66/p51. (B) +6 nt extension assay was performed as described in
Figure 4 legend and the results were presented graphically in lower
panel. Shown are the mean values ± SD of 3 experiments. (C) Viral
infectivity assay was performed as described in Figure 2 legend.
*, P <0.05 compared to values obtained with virions produced from
the cells treated with siRNACon, siRNARHA or siRNAHAP alone (lane 1, 2,
or 3 respectively).
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RHA promotes annealing of tRNALys3 to viral RNA
[14,15] and the observation that HAP95 associates with
the RT region of HIV-1 Pol in the cell and upon over-
expression, is incorporated into HIV-1 particles (Figure 1).
Knockdown of HAP95 from cells does not affect theproduction of virus particles and the packaging of viral
RNA or cellular tRNALys3, a primer for reverse transcrip-
tion, into virus particles, but results in the reduced
amounts of tRNALys3 annealed on the viral RNA. The im-
paired tRNALys3 annealing by decreasing cellular HAP95
was further deteriorated by knockdown of RHA, suggest-
ing a potential cooperation between those two proteins in
the cell.
The cooperation between HAP95 and RHA was initially
described for simian type D retrovirus replication in which
HAP95 binds to RHA and synergizes significantly with
RHA to activate CTE-mediated gene expression and pro-
motes nuclear export of unspliced mRNA [22,23]. How-
ever, the cooperative effects between HAP95 and RHA on
tRNALys3 annealing found in this report seem ‘uncon-
ventional’ since the HAP95 inhibits the activity of RHA
in vitro (Figure 6).
Several pieces of data favor a model in which an initial
annealing of tRNALys3 by Gag occurs in the cytoplasm
prior to viral budding and protein processing, followed
by a re-annealing of the tRNALys3 by NCp7 after protein
processing [9]. Annealing of tRNALys3 is also facilitated
by Gag in vitro [11]. Recently, a highly abundant small
18-nt RNA that is antisense to the PBS of HIV-1 was de-
tected in the cells in which HIV-1 was replicating [27].
This 18-nt RNA apparently was generated by cellular
RNAi machinery from the double-stranded RNA hybrid
formed by the HIV-1 PBS and the 3’ end of the human cel-
lular tRNALys3, therefore providing direct evidence for the
annealing of tRNALys3 to HIV-1 RNA in the cytoplasm.
Since RHA accompanies HIV-1 RNA from transcription in
the nucleus until being assembled into progeny virion
(Summarized in Figure 7), the double-stranded RNA re-
gions formed in the cytoplasm by annealing of tRNALys3 to
HIV-1 RNA would also be subjected to the activity of
RHA, which could remove the annealed tRNALys3 from
viral RNA by unwinding double-stranded RNA region. To
support this hypothesis, we have examined the ability of
RHA to remove tRNALys3 that has been annealed to the
viral RNA in the cells (Figure 6C). tRNALys3-annealed viral
RNA was isolated from HIV-1 virion produced in non-
siRNA-treated 293T cells, and then exposed to enzymati-
cally active RHA at 37°C for 30 min in the presence or ab-
sence of 1 mM ATP or GST-HAP95. The viral RNA was
then deproteinized and the +6 nt extension assay was per-
formed in an in vitro reverse transcription reaction contain-
ing 32P-dGTP. The extended tRNALys3 became radioactive
and was resolved in denaturing 6% polyacrylamide gels.
Control panel of Figure 6C shows the +6 nt extension of a
DNA primer that was annealed to viral RNA in vitro to
verify the presence of viral RNA in the reverse transcrip-
tion mixtures. The radioactive tRNALys3 was no longer de-
tectable after RHA treatment in the presence of ATP,
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Figure 6 HAP95 inhibits activity of RHA in vitro. (A) Purification of GST-tagged HAP95. CBB, The proteins in SDS-PAGE were stained with Commassie
brilliant blue R250. WB, Western blots of proteins purified from 293E cells were probed with anti-GST or anti-HAP95. M, protein size marker shown in kDa.
(B) Annealing of tRNALys3 to viral RNA in vitro. 100 fmoles of tRNALys3 were annealed to 30 fmoles of 32pCp-labeled synthetic viral RNA by Gag in the
presence of RHA, GST-HAP95, or both RHA and GST-HAP95. Purified GST was used in place of GST-HAP95 as a negative control. The annealing reaction
mixture was incubated at 25°C for 40 min, separated in 5% native polyacrylamide gel, and visualized using a PhosphorImager instrument. Unannealed
(UA) viral RNA and the slow-, middle-, and fast-migrating tRNALys3-annealed viral RNA bands are indicated. (C) RHA disrupts tRNALys3-viral RNA complex
isolated from HIV-1 virion. tRNALys3-annealed viral RNA was isolated from HIV-1 particles, exposed to RHA in the presence or absence of ATP and/or
GST-HAP95, extended by reverse transcription in the presence of 32P-dGTP, and separated in denaturing 6% polyacrylamide gel. The control panel is the





















Figure 7 Model summarizing the involvement of RHA in multiple steps of HIV-1 RNA metabolism and the proposed role of HAP95 in the
annealing of tRNALys3 to viral RNA. RHA mainly associates with the structured 5’-UTR of HIV-1 RNA during virus production. RHA stimulates the
accumulation of viral RNA in the nucleus and then by remodeling the highly structured 5’-UTR to facilitate both the viral translation and the annealing
of tRNALys3 to viral RNA in the cytoplasm, and finally assembles into progeny virions. HAP95 is likely to be employed to transiently block the activity of
RHA to protect the annealed tRNALys3 on viral RNA in the cell from being removed by RHA’s activity prior to the budding of virus particles.
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http://www.retrovirology.com/content/11/1/58RNA complex that formed in the cell. However, the pres-
ence of GST-HAP95 blocked this destructive effect of
RHA. The results suggest that it would be necessary to
regulate RHA’s activity during HIV-1 production.
RHA has been shown to participate in multiple steps
of HIV-1 RNA metabolism [28]. RHA mainly associates
with the structured 5’-UTR of HIV-1 RNA during virus
production [29]. RHA stimulates the accumulation of
viral RNA in the cell [30] and facilitates the generation
of unspliced viral RNA [31]. In the cytoplasm, RHA may
remodel the structured 5’-UTR of HIV-1 RNA to enhance
the translation of viral RNA [32,33] and also render the
viral RNA susceptible to be annealed by tRNALys3[14]. Ac-
cording to the observations in this study, it would be
plausible to propose that HAP95 may inhibit temporarily
the activity of RHA after the placement of tRNALys3 on
the viral RNA prior to viral budding (Figure 7), as HAP95
is able to traffic to the cellular site for HIV-1 particle as-
sembly by association with Pol protein (Figure 1).
Conclusion
The results support a hypothesis that HAP95 may transi-
ently block RHA’s activity to protect the annealed tRNALys3
on viral RNA in the cells from removing by RHA during
the packaging of RHA into virus particles, thus facilitating
the annealing of tRNALys3 to HIV-1 RNA.
Methods
Plasmids
SVC21.BH10 is a simian virus 40-based vector that con-
tains full-length wild-type HIV-1 BH10 proviral DNA
[34]. Plasmid hGag/Gag-Pol is a gift from Drs. Y. Huang
and G. Nabel at the Vaccine Research Center, National
Institute of Allergy and Infectious Diseases (NIAID),
National Institutes of Health (NIH), Bethesda, MD [35].
The Gag and Gag-Pol proteins encoded by this plasmid
have amino acid sequences identical to that of HIV-1
strain NL4-3, but the mRNA sequences have their codons
optimized for efficient translation in mammalian cell.
The DNA fragment encoding Pol was amplified from
hGag/Gag-Pol by PCR using primers (forward, 5’-ACTA
GTGAATTCAGGGAAGATCTGGCCTTCCCA-3’; re-
verse, 5’-CGATCGGATATCCTAGTCCTCGTCCTGG
CGGCT-3’), digested by EcoRI and EcoRV, and then
inserted into pcDNA3-N-TAP (provided by Drs. Nahum
Sonenberg and Anne-Claude Gingras, McGill university)
to yield pcDNA3-N-TAP-hPol expressing TAP-tagged Pol.
DNA fragments encoding reverse transcriptase (RTp66)
or integrase (INp32) were amplified from hGag/Gag-Pol




TCGAC-3’, forward; 5’-CGGGGCGCGCCCTAGTCCTCGTCCTGGCGGCT-3’, reverse), digested by NotI and
AscI, and then inserted into plasmid pN-His to yield
pN-His-RTp66 or pN-His-INp32 that expresses 6 ×
His-tagged RTp66 or INp32 respectively. HAP95 cDNA
was amplified by RT-PCR from 293T cells using pri-
mer pair (5’-CGGGCGGCCGCCAGCTACACAGGCT
TTGTC-3’, forward; 5’-CGGGGCGCGCCTCATCACG
GGGCGCCCCCGCC-3’, reverse), digested by NotI and
AscI, and then inserted into pcDNA3.1-Flag or pTT5SGST
to construct pcDNA3.1-Flag-HAP95 or pTT5SGST-
HAP95 encoding N-terminally Flag-tagged or GST-
tagged HAP95. pcDNA3.1-Flag-HAP95 was mutated by
fusion PCR using fusion primers hap-mu-F (5’-CGAAT
TACGGATACGGGATGGCCACTTCACACTCTT-3’) and
hap-mu-R (5’-ATCCCGTATCCGTAATTCGTGGTGTTA
TCCTGGCCA-3’) to yield pcDNA3.1-Flag-HAP95-r that
produces mRNA resistant to siRNAHAP, but encodes the
identical amino acid residues as pcDNA3.1-Flag-HAP95.
Plasmids pcDNA3.1Gag-CTE and pcDNA3.1Gag/Gag-
Pol-CTE (provided by Dr. Min Wei, National center for
AIDS/STD control and prevention, Chinese center for dis-
ease control and prevention, Beijing, China) encoding HIV-1
BH10 Gag or Gag plus Gag-Pol were used to produce
HIV-1 VLP by transfection into 293Tcells. The extracellu-
lar VLPs were purified by step sucrose centrifugation.
Cell culture
SupT1 cells were cultured in RPMI 1640 medium sup-
plemented with 10% fetal bovine serum (FBS), 1%
penicillin-streptomycin, and 1% glutamine and were in-
fected with HIV-1 produced from 293T cells. TZM-bl is
a HeLa cell line expressing CD4 and CCR5 and contain-
ing a reporter luciferase gene driven by HIV-1 long ter-
minal repeat promoter [36]. This cell line was used for
measuring HIV-1 infectivity and was obtained from NIH
AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH. 293T and TZM-b1 cells were
grown in complete Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with penicillin, streptomycin, and
10% FBS. Transfection of 293T cells was done using Lipo-
fectamine 2000 (Invitrogen). HEK 293E cell is a stably
transfected HEK293 cell line expressing Epstein-Barr virus
nuclear antigen-1 and supports amplification of plas-
mids containing the replication origin region (OriP) of
Epstein-Barr virus, resulting in high expression of proteins
encoded for by these plasmids [37]. This cell line was ob-
tained from Mr. Yves Durocher (Biotechnology Research
Institute, Montreal, Canada) and was used to express
and purify GST-tagged HAP95, grown in F17 medium
(Invitrogen) supplemented with 2 mM L-glutamine and
0.1% Pluronic F-68 (GIBCO), and transfected by 25 kDa
linear Polyethylenimine (PEI, pH7.0) (Polysciences Inc).
To establish a cell line stably expressing TAP-Pol,
293T cells were transfected with pcDNA3-N-TAP-hPol
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G418. Established cell lines were confirmed by Western blot
analysis using rabbit polyclonal antibody against HIV-1 RT.
A cell line expressing only TAP tag was established as well
by transfecting 293T cells with plasmid pcDNA3-N-TAP
and used as a control in protein complex purification.
Purification and identification of cellular proteins bound
to TAP-Pol
We followed the TAP procedure to purify TAP-Pol com-
plex as described [15]. Briefly, 9 × 108 293T cells stably-
transfected with pcDNA3-N-TAP-hPol or pcDNA3-N-TAP
were collected, washed with ice-cold phosphate-buffered
saline, and then lysed in buffer containing 50 mM HEPES
(pH 8.0), 100 mM KCl, 2 mM EDTA, 0.1% Nonidet P-40,
2 mM dithiothreitol, 10 mM NaF, 0.25 mM NaOVO3,
5 nM Okadaic acid, 5 nM calyculin A, 50 mM glycerol-
phosphate, 10% glycerol, and protease inhibitors (Roche
Diagnostics). After centrifugation at 19,800 × g for 30
minutes, supernatants were incubated with IgG beads
(Amersham Biosciences) at 4°C overnight. The TAP-Pol-
bound IgG beads were washed with lysis buffer and TEV
buffer (10 mM HEPES, pH 8.0, 150 mM NaCl, 0.1% Noni-
det P-40, 0.5 mM EDTA, and 1 mM dithiothreitol) and then
incubated with TEV protease (Invitrogen) in TEV buffer at
16°C for 2 h to release TAP-Pol proteins. The supernatants
were further incubated with calmodulin beads (Amersham
Biosciences) in calmodulin-binding buffer (10 mM HEPES,
pH 8.0, 150 mM NaCl, 1 mM MgOAc, 1 mM imidazole,
0.1% Nonidet P-40, 2 mM CaCl2, and 10 mM β-
mercaptoethanol). After washing with calmodulin-binding
buffer and calmodulin rinsing buffer (100 mM HEPES, pH
8.0, 75 mM NaCl, 1 mM MgOAc, 1 mM imidazole, and 2
mM CaCl2), TAP-Pol protein complex was eluted by using
a buffer containing 200 mM HEPES, pH 8.0, 75 mM NaCl,
1 mM MgOAc, 1 mM imidazole, and 25 mM EGTA. The
eluted proteins were separated in 10% SDS-PAGE followed
by Coomassie Brilliant Blue R250 staining. The visible pro-
tein bands were selectively excised, in-gel-digested with
trypsin, and subjected to liquid chromatography/mass
spectrometry analysis (Calgary University Sams Centre).
Viral RNA isolation
The amounts of HIV-1 particles were determined by
measuring the level of CAp24 antigen using the enzyme-
linked immunosorbent assay (ELISA). The extracellular
HIV-1 particles were purified by step sucrose centrifuga-
tion. The viral RNA was isolated from purified virus par-
ticles using guanidinium isothiocyanate as described [38]
and dissolved in 5 mM Tris buffer (pH 7.5).
Packaging of tRNALys3 and viral RNA in HIV-1 particles
The abundance of tRNALys3 or HIV-1 genomic RNA in
virus particles was determined by dot blot hybridization asdescribed [39]. Briefly, each sample of total viral RNA iso-
lated from equal amounts of purified virus particles was
blotted onto Hybond N + nylon membranes (Amersham
Pharmacia) and probed with a 32P-labeled 18-mer DNA
specific for the 3’ end of tRNALys3 (5’-TGGCGCCCGAA
CAGGGAC-3’) or 32P-labeled DNA oligonucleotides that
are complementary to 3 different regions of HIV-1 gen-
omic RNA (p2830, 5’-AGGCTGTACTGTCCATTTAT
CAGGATGGAGT-3’; p5671, 5’-TATTGCTATTATTATT
GCTACTACTAATGCT-3’; p8304, 5’-TGTGGCGAATA
GCTCTATAAGCTCCTT-3’). The radioactive signals were
detected and quantitated using a PhosphorImager instru-
ment (Amersham Pharmacia).
Primer extension assay
tRNALys3-primed initiation of reverse transcription was
analyzed by measuring the ability of tRNALys3 to be ex-
tended by one nucleotide (+1 nt) or six nucleotides
(+6 nt) in an in vitro reverse transcription reaction. The
amounts of total viral RNA used in the reactions were
first quantitated by dot blot hybridization as described
above and were further determined by measuring the
ability of a DNA primer (5’-TCTAATTCTCCCCCGCT
TAATACTGACGCT-3’) annealed at room temperature
to the viral RNA to prime a +6 nt extension (5’-CTCGCA-
3’). Equal amounts of total viral RNA were used as the
source of primer tRNALys3 annealed in vivo to viral gen-
omic RNA. The sequence of the first six deoxynucleoside
triphosphates incorporated is 5’-CTGCTA-3’. For +6 nt
extension, reactions were carried out in a volume of 20 μl
containing 50 mM Tris–HCl (pH 7.8), 100 mM KCl,
10 mM MgCl2, 10 mM dithiothreitol, 0.2 mM dCTP,
0.2 mM dTTP, 5 μCi of α-32P-dGTP (0.16 μM), and
0.05 mM ddATP (instead of dATP, thereby terminating the
reaction at the sixth base), 50 ng of HIV-1 RT, and RNase
inhibitor (Ambion). For +1 nt extension, reactions were
carried out in a volume of 20 μl RT reaction mixture con-
taining only 0.16 μM α-32P-dCTP. Reaction mixture was
incubated at 37°C for 15 min. The extended tRNALys3 was
precipitated with isopropanol and separated in a 6% de-
naturing polyacrylamide gel.
Real-time PCR
Real-time PCR was performed using PerfeCta SYBR
green FastMix (Quanta BioScience Inc.) as instructed by
the manufacturer’s instructions. The PCR conditions
were 95°C for 5 s, 60°C for 15 s, and 72°C for 10 s. All
analyses were done in triplicate, with triplicate samples
in each experiment.
Quantitation of newly synthesized HIV-1 cDNA, viral
genomic RNA, and tRNALys3
Real-time PCR was carried out to examine the synthesis
of viral cDNA intermediates in a permissive cell line
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duced from siRNA–treated 293T cells. 3 × 106 SupT1
cells were infected with equal amounts of purified vi-
rions (100 ng of CAp24) at 4°C for 2 h. The cells were
then washed twice with phosphate-buffered saline, and
incubated at 37°C. At 16 hours post-infection, the cells
were collected and washed with phosphate-buffered sa-
line. The cellular DNA was extracted using the DNeasy tis-
sue kit (Qiagen). Equal amounts of cellular genomic DNA
were used in real-time PCR to quantitate viral cDNA inter-
mediates containing sequence for R-U5 using the following
primer set: 5’-TTAGACCAGATCTGAGCCTGGGAG-3’/
5’-GGGTCTGAGGGATCTCTAGTTACC-3’ [40]. Total
cellular RNA was also isolated from HIV-1-infected SupT1
cells using TRIzol (Invitrogen). The amount of β-actin
mRNA was quantitated using real-time RT-PCR as de-
scribed [41] as an internal control. The total cellular
RNA containing equal amount of β-actin mRNA was
used to generate cDNA of the viral genomic RNA
using SuperScript reverse transcriptase III (Invitrogen)
and the primer (5’-AGCCTTCTCTTCTACTACTTT
TACCC-3’). The amount of resultant cDNA was de-
termined by real-time PCR using the following primer
set: 5’-CTACAACCATCCCTTCAGACAGGAT-3’/5’-TC
CTGTGTCAGCTGCTGCTTGCTGT-3’. These primers
were also used in real-time RT-PCR to quantitate viral
RNA isolated from equal amounts of HIV-1 virions. The
amount of tRNALys3 in the same viral RNA sample was




Single-cycle infectivity assay was performed as described
[14]. 105 TZM-bl cells were challenged with viruses corre-
sponding to 5 ng of CAp24. The induced activity of lucif-
erase in cell lysates was measured using luminometer
Lumat LB9507 (EG&G Berthold, Bad Wildbad, Germany).
Isolation of HIV-1 core
HIV-1 core was isolated by following the procedures de-
scribed [43]. Briefly, culture medium was clarified by cen-
trifugation and then virus particles were concentrated
through a step cushion of sucrose (15% and 65%, wt/wt)
in phosphate-buffered saline. The virus pellet was slowly
resuspended in phosphate-buffered saline and then mixed
with an equal volume of 200 mM NaCl-100 mM morpho-
linepropanesulfonic acid (MOPS, pH 7.0). Triton X-100
was added to a final concentration of 0.5% to lyse virions
for 2 min at room temperature. HIV-1 cores were recov-
ered by centrifugation in a microcentrifuge at full speed
(13,400 g) for 8 min at 4°C, washed twice with 100 mM
NaCl-50 mM MOPS (pH 7.0), resuspended in the same
buffer, and analyzed immediately by Western blotting.siRNA
Small interfering RNA (siRNA) against RHA has been
described [14]. siRNAs against HAP95 (siRNAHAP) were
generated using the target sequence 5’-CCAACUAUGG
GUAUGGUAU-3’, and purchased from Invitrogen. Lipo-
fectamine 2000 (Invitrogen) was used to introduce siRNAs
into 293T cells. The endogenous RHA and HAP95 were
measured by Western blot analysis using specific anti-
bodies. The level of β-actin was measured as an internal
control.Purification of proteins
Purification of RHA and HIV-1 Gag-pr55 has been de-
scribed [14]. The procedures developed by Durocher et al.
[44] were followed for purifying glutathione-s-transferase
(GST) or GST-tagged HAP95 from 293E cells. Briefly, the
cells were transfected with pTT5-SGST or pTT5-SGST-
HAP95. The transfected cells were collected at 48 hours
later, washed with ice-cold phosphate-buffered saline, and
then lysed in buffer containing 50 mM NaH2PO4,
300 mM NaCl, 0.5% Triton-X 100, 10% glycerol, protease
inhibitor cocktail tablets (Roche), pH7.4. The cell lysates
were clarified by centrifugation at 19,800 g for 30 min at
4°C. Glutathione Sepharose high performance (GE health-
care) was added into supernatant and incubated at 4°C for
2 hours to capture GST or GST-HAP95. After extensive
washes, the protein was eluted by 33 mM reduced gluta-
thione (Fisher Scientific) in elution buffer containing
50 mM Tris–HCl, pH8.0 and 10% glycerol. Purified pro-
teins were dialyzed against 20 mM Tris–HCl, pH7.5,
150 mM NaCl, 20 mM KCl, 2 mM MgCl2, 2 mM dithio-
threitol, 10% glycerol, and then stored at −80°C.In vitro tRNALys3 annealing assay
The first 386 nts of 5’-UTR of HIV-1 RNA and tRNALys3
were synthesized by in vitro transcription using T7 RNA
polymerase (T7 MEGAscript kit, Ambion) [14]. Synthetic
viral RNA was labeled with [5’-32P] Cytidine 3’,5’-bis
(phosphate) (32pCp) using T4 RNA ligase (Fermentas). 30
fmoles of 32pCp-labeled viral RNA and 100 fmoles of
tRNALys3 were first incubated with 1,000 fmoles of RHA
at 37°C for 10 minutes in the presence of 3,000 or 6,000
fmoles of GST or GST-tagged HAP95 in 20 μl reaction
mixture containing 10 mM Tris–HCl, pH 8.0, 50 mM
KCl, 2 mM MgCl2, 2 mM dithiothreitol, 2 units RNasin,
2.5 mM NaH2PO4, 15 mM NaCl, and 2 mM ATP. Gag
(20,000 fmoles) was then added and incubated at 25°C
for 40 min. The reaction was stopped by addition of 5 μl
solution containing 2% SDS, 10 mM CaCl2, 250 μg/ml
proteinase K, 40% glycerol, bromophenol blue, and
xylene cyanol. Twenty minutes later, the samples were
electrophoresed on a 5% native polyacrylamide gel in
0.5 × Tris-borate-EDTA buffer (TBE). 32pCp-labeled
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PhosphorImager instrument.Protein co-precipitation
Protein complexes containing His-tagged protein were pre-
cipitated from cellular lysates by using Ni-nitrilotriacetic
acid (NTA) agarose (Qiagen). The transfected cells were
lysed in lysis buffer (50 mM NaH2PO4, pH8.0, 150 mM
NaCl, 10 mM imidazole, 0.5% Triton-X 100, 10% glycerol,
protease inhibitor cocktail tablets) and then centrifuged at
10,000 g for 10 min at 4°C. Ni-NTA agarose was added into
the clarified supernatant and incubated at 4°C for 2 hours.
Precipitated protein complex was eluted by 250 mM imid-
azole and analyzed by Western blotting.Western blot analysis
The protein samples were resolved in SDS-PAGE and then
blotted onto nitrocellulose membranes (Bio-Rad). Western
blots were probed with rabbit anti-HIV RT, mouse anti-
p24 [45], mouse anti-gp120 [46,47] (NIH AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID,
NIH), rabbit anti-HAP95 (Proteintech Group Inc), mono-
clonal anti-human β-actin (Sigma), polyclonal rabbit anti-
RHA (Novus Biologicals), or monoclonal anti-polyHistidine
(Sigma). Horseradish peroxidase-conjugated secondary
antibodies used were either anti-rabbit immunoglobulin
(1:5,000 dilution) (Amersham Pharmacia Biotech) or anti-
mouse immunoglobulin (1:5,000 dilution) (Rockland
Immunochemicals). Protein bands were detected by enhanced
chemiluminescence (ECL, Perkin-Elmer Life Science Inc).Statistical analysis
The one tailed Student’s t test was employed in statis-
tical analyses. The lowest level of significance was set at
P < 0.05.
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